The impact of COVID-19 on the health plan enterprise appears to be practical and functional rather than strategic and financial.
Ira Studin, PhD, MPH
Advertisement
Articles by Ira Studin, PhD, MPH
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.
Oncology economics is the product of driving forces in the health insurance market that are intrinsic to oncology in managed care and unlikely to change.
Advertisement
Latest Updated Articles
Boomerang Effect Of Gene Therapy on Oncology ContractingFebruary 11th 2019
Oncology EconomicsMay 15th 2018
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting
4
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
5